Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03838510 · ClinicalTrials.gov registry record · NA
Repeated-dose Behavioral Intervention to Reduce Opioid Overdose
A NA study of Opioid-Related Disorders and Drug Overdose, sponsored by San Francisco Department of Public Health.
- Completed
- Registry status
- NA
- Development phase
- 268
- Enrollment target
- 2
- Study locations
NCT03838510: Completed NA study of Opioid-Related Disorders and Drug Overdose, sponsored by San Francisco Department of Public Health.
NCT03838510 is a NA study of Opioid-Related Disorders and Drug Overdose that has completed, run by San Francisco Department of Public Health. The registered enrollment target is 268 participants, below the 341-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (21% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03838510, a NA study of Opioid-Related Disorders and Drug Overdose, has completed, sponsored by San Francisco Department of Public Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 268 participants
- Enrollment target
- 2
- Study locations
Study Summary
REBOOT is a randomized trial of a repeated-dose brief intervention to reduce overdose and risk behaviors among naloxone recipients with opioid use disorder. It includes an established overdose education curriculum within an Informational-Motivation-Behavior (IMB) model. This study will test the efficacy of REBOOT vs attention-control.
Primary Outcome
Number of overdose events will be measured by self-report via timeline follow-back (TLFB) assessment, ED/EMS records, and Vital records.
Conditions Studied
Interventions
- BEHAVIORAL REBOOT
Study Locations (2)
California
- San Francisco Department of Public Health - San Francisco
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2019-04-22 |
| Est. Completion | 2023-12-12 |
| Phase | NA |
What the finished NCT03838510 record still lists
NCT03838510 is an interventional study that assigns participants to a tested intervention. The registered 268 participants enrollment target is mid-sized for trials with a published cap, below the 341-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (21% lower).
The record links to 2 conditions, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which REBOOT is the first listed.
NCT03838510 reports a single indexed study location in California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03838510 about?
NCT03838510 is a clinical study titled "Repeated-dose Behavioral Intervention to Reduce Opioid Overdose". REBOOT is a randomized trial of a repeated-dose brief intervention to reduce overdose and risk behaviors among naloxone recipients with opioid use disorder. It includes an established overdose education curriculum within an Informational-Motivation-Behavior (IMB) model. This study will test the effi...
What is the current status of trial NCT03838510?
This trial is currently completed. It is a NA study. The enrollment target is 268 participants. The study started on 2019-04-22. Estimated completion is 2023-12-12.
What conditions does trial NCT03838510 study?
This clinical trial studies the following conditions: Opioid-Related Disorders, Drug Overdose.
What interventions are being tested in trial NCT03838510?
The interventions under investigation include: REBOOT (BEHAVIORAL).
Who is sponsoring clinical trial NCT03838510?
This trial is sponsored by San Francisco Department of Public Health, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03838510 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03838510's enrollment target sits among peer trials
268 13th of 47 higher than 35 of 47 other Opioid-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care
RECRUITING · NA
-
Developing a Smartphone Application to Support Veteran Opioid Use Disorder Treatment
RECRUITING · NA
-
OUD Smartphone Services
ACTIVE NOT RECRUITING · NA
-
Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing
ACTIVE NOT RECRUITING · NA
-
Healthy Opioid Prescription Engagement
ACTIVE NOT RECRUITING · NA
-
Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
- NCT05797831 · 268 participants · Phase 2
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- NCT05997381 · 268 participants · NA
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
- NCT06233461 · 268 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI